Stock Price Movement and Market Context
On 28 Nov 2025, Sandu Pharmaceuticals recorded an intraday low of Rs.37.01, representing a drop of 3.85% for the day. This decline followed two consecutive days of gains, signalling a reversal in short-term momentum. The stock underperformed its sector by 3.53% on the same day, reflecting pressure relative to its Pharmaceuticals & Biotechnology peers.
Currently, Sandu Pharmaceuticals is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning indicates a sustained downward trend over multiple time horizons, which contrasts with the broader market’s performance. The Sensex opened flat but moved into positive territory, trading at 85,755.55 points, just 0.35% shy of its 52-week high of 86,055.86. The benchmark index is supported by mega-cap stocks and remains above its 50-day moving average, with the 50 DMA positioned above the 200 DMA, signalling a generally bullish market environment.
Financial Performance and Historical Returns
Sandu Pharmaceuticals’ one-year stock return stands at -34.46%, a stark contrast to the Sensex’s 8.49% gain over the same period. The stock’s 52-week high was Rs.62.80, underscoring the extent of the recent decline. Over the past three years, the company has consistently underperformed the BSE500 index, reflecting persistent challenges in maintaining competitive growth and profitability.
Net sales for the quarter ending March 2025 were reported at Rs.14.07 crores, marking the lowest quarterly sales figure in recent periods. Operating profit has shown an annual growth rate of 17.92% over the last five years, while net sales have grown at a more modest annual rate of 4.69%. These figures suggest a relatively slow expansion in revenue alongside moderate improvements in operational profitability.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Profitability and Debt Servicing Capacity
The company’s average Return on Equity (ROE) over recent periods is 3.73%, indicating limited profitability relative to shareholder equity. This figure is modest compared to industry standards and suggests restrained returns on invested capital.
Sandu Pharmaceuticals’ ability to service its debt is reflected in an average EBIT to interest ratio of 1.92. This ratio points to a relatively tight margin between earnings before interest and tax and interest obligations, implying limited cushion for debt servicing under current earnings levels.
Despite these challenges, the stock’s valuation metrics show a Price to Book Value ratio of 0.9, which is below the average historical valuations of its peers. This suggests that the market is pricing the stock at a discount relative to its book value, potentially reflecting the company’s financial performance and market sentiment.
Shareholding and Market Position
The majority of Sandu Pharmaceuticals’ shares are held by non-institutional investors, which may influence trading patterns and liquidity. The company operates within the Pharmaceuticals & Biotechnology sector, a space characterised by both innovation and regulatory complexities.
While the broader sector has shown resilience, Sandu Pharmaceuticals’ stock has not mirrored this trend, as evidenced by its underperformance relative to sector indices and the Sensex.
Considering Sandu Pharmaceuticals ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Recent Profit Trends and Valuation Metrics
Over the past year, Sandu Pharmaceuticals’ profits have shown a rise of 10.9%, despite the stock’s negative return of 34.46%. This divergence between profit growth and stock price performance may reflect market concerns about sustainability and broader financial health.
The company’s PEG ratio stands at 2.2, indicating the relationship between price, earnings growth, and valuation. This figure suggests that the stock’s price relative to earnings growth is higher than one might expect for a company with its current growth rate.
Sandu Pharmaceuticals’ stock price has been influenced by multiple factors, including its financial metrics, sector dynamics, and overall market conditions. The stock’s position below all major moving averages and its recent 52-week low highlight the challenges it faces in regaining upward momentum.
Summary of Key Metrics
To summarise, Sandu Pharmaceuticals’ key financial and market indicators as of 28 Nov 2025 include:
- New 52-week low price: Rs.37.01
- One-year stock return: -34.46%
- Sensex one-year return: 8.49%
- Net sales (quarter ending Mar 2025): Rs.14.07 crores
- Average ROE: 3.73%
- Average EBIT to interest ratio: 1.92
- Price to Book Value ratio: 0.9
- Profit growth over past year: 10.9%
- PEG ratio: 2.2
These figures provide a comprehensive view of the company’s recent performance and valuation context within the Pharmaceuticals & Biotechnology sector.
Market Outlook and Positioning
While the Sensex and mega-cap stocks maintain a generally positive trajectory, Sandu Pharmaceuticals’ stock remains under pressure. The company’s financial indicators and stock price trends reflect a cautious market stance, with the stock trading at a discount relative to its peers.
Investors and market participants will continue to monitor the company’s financial disclosures and sector developments to assess any shifts in its market position.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
